Here, BioSpace looks back at the biggest acquisition deals of 2025. Target: Intra-Cellular Therapies Acquisition date: ...

The cost of the monkeys — a proxy for the volume of clinical trials — is projected to reach Rmb150,000 ($21,000) at the start ...

Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles ...

Shares of pharmaceutical giant Pfizer (NYSE: PFE) are currently trading below $25, marking a decline of approximately 60% ...

ASCO GU 2025 had groundbreaking advancements in genitourinary cancer treatments, focusing on prostate cancer, renal cell ...

Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration ...

It's quite possible for the new year to fulfill this ambitious name. Investing $122,100 in these three high-yield dividend ...

Pfizer's oral HER2 inhibitor Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive metastatic breast cancer, based on now-revealed data from the HER2CLIMB-05 study ...

It has been a busy week for news in the superheated obesity category, headlined by news that Pfizer has licensed a therapy from a subsidiary of China's Fosun Pharma, in a deal that includes $150 ...

The price hikes come even as the Trump administration pressures pharmaceutical companies to lower costs for patients and ...

In 2025, federal health agencies dismantled precedents in vaccine guidance, fracturing state-federal alignment and fueling concerns about public health guidance. HHS Secretary Robert F. Kennedy Jr.

The costs of at least 350 drugs in the U.S. are expected to rise in 2026, according to a new analysis, despite many of the ...